Cytokinetics Launches Myqorzo in Germany
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Cytokinetics announced the first commercial European launch of Myqorzo in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. "Bringing Myqorzo to Europe marks an exciting new chapter for Cytokinetics as we extend our reach to more patients with symptomatic obstructive hypertrophic cardiomyopathy," said Joseph Dagher, senior VP and head of Europe, Cytokinetics. The availability of Myqorzo in Germany follows European Commission approval in February, which was based on positive results from the pivotal Phase 3 clinical trial SEQUOIA-HCM.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYTK
Wall Street analysts forecast CYTK stock price to rise
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 78.110
Low
61.00
Averages
89.33
High
136.00
Current: 78.110
Low
61.00
Averages
89.33
High
136.00
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cytokinetics Launches Corporate Giving Program for Non-Profits
- Program Launch: Cytokinetics has announced its annual Corporate Giving Program, which aims to provide charitable donations of up to $20,000 to eligible non-profit organizations to support equitable healthcare initiatives for cardiovascular disease and science education.
- Application Deadline: The deadline for applications for this program is August 3, 2026, encouraging 501(c)(3) organizations in the U.S. to apply, particularly those focused on science education and essential services for at-risk communities.
- Targeted Regions: The donations will primarily focus on the San Francisco Bay Area and Greater Philadelphia Region, aiming to enhance healthcare services and educational opportunities in these areas through funding health equity initiatives, thereby improving the quality of life for local residents.
- Corporate Mission: Diane Weiser, Senior Vice President of Cytokinetics, stated that this program reflects the company's commitment to the communities it serves, aiming to provide everyone with a fair chance at health and opportunity, further solidifying its image of social responsibility in the biopharmaceutical industry.
See More
Cytokinetics Launches MYQORZO in Germany Following U.S. Success
- European Market Launch: Cytokinetics has launched MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults, marking a significant expansion into the European market that is expected to enhance the company's market share in cardiovascular therapeutics.
- Clinical Trial Backing: The launch follows the European Commission's approval in February 2026, based on positive results from the SEQUOIA-HCM Phase 3 trial, which demonstrated robust efficacy and safety, improving patients' exercise capacity and symptoms, thereby reinforcing Cytokinetics' leadership in muscle biology.
- Significant Treatment Effects: Clinical data indicates that treatment with MYQORZO for 24 weeks resulted in a peak oxygen uptake (pVO2) increase of 1.76 mL/kg/min compared to baseline, versus 0.0 mL/kg/min in the placebo group, highlighting the drug's potential to significantly enhance patient quality of life.
- Increased Patient Hope: The availability of MYQORZO in Germany provides new treatment options for oHCM patients across Europe, reflecting Cytokinetics' commitment to the global HCM community and the potential to improve patient quality of life through personalized treatment approaches.
See More
Cytokinetics to Host Third Annual Muscle Biology Symposium
- Symposium Date and Venue: Cytokinetics will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium on May 29, 2026, at the Mission Bay Conference Center in San Francisco, CA, from 8 AM to 5 PM Pacific Time, aimed at fostering dialogue and discovery in muscle biology.
- Registration Details: The symposium is free for attendees, but capacity is limited, requiring interested parties to register online by May 22, 2026, reflecting the company's commitment to advancing scientific communication.
- Keynote and Agenda: The event will feature keynote presentations from distinguished experts covering cardiac biology, skeletal muscle biology, and emerging treatment modalities, with the goal of driving advancements in the biological understanding and treatment of muscle-related diseases.
- Company Background and Development: Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of pioneering innovations in muscle biology, currently developing multiple potential new medicines for cardiac muscle dysfunction, showcasing its ongoing investment and growth potential in the biopharmaceutical sector.
See More
Cytokinetics Presents Favorable Clinical Data for MYQORZO at ESC Heart Failure 2026
- Clinical Data Presentation: Cytokinetics showcased new clinical data for MYQORZO (aficamten) at the ESC Heart Failure 2026 Congress, emphasizing its effectiveness and safety compared to metoprolol, further solidifying its potential in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Sex Differences Analysis: The MAPLE-HCM trial revealed that MYQORZO demonstrated similar improvement effects in female patients compared to males, despite women entering the trial with more severe baseline characteristics, indicating the drug's consistent efficacy across genders, which may enhance personalized clinical treatment.
- Long-term Safety Data: A prospective analysis from FOREST-HCM indicated that long-term treatment with MYQORZO for up to 96 weeks did not increase the incidence of arrhythmias, reinforcing its safety profile, particularly in patients who discontinued beta-blocker therapy, thereby boosting confidence in its clinical application.
- Left Atrial Remodeling Improvement: Expanded insights from SEQUOIA-HCM provided the first analysis of MYQORZO's effects on left atrial function, showing significant improvements in left atrial mechanics, potentially offering new therapeutic avenues for enhancing functional capacity in oHCM patients.
See More
Cytokinetics Closes $805 Million Public Offering
- Offering Size: Cytokinetics successfully closed a public offering of 11,338,028 shares at $71.00 per share, raising approximately $805 million, indicating strong market demand for its stock.
- Underwriter Lineup: The offering was managed by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, reflecting confidence from investment banks in Cytokinetics' future growth and potentially enhancing its market position.
- Registration Statement: The securities were offered under a shelf registration statement filed with the SEC on February 27, 2025, ensuring compliance and streamlining the offering process, which boosts investor confidence.
- Business Context: Cytokinetics focuses on cardiovascular biopharmaceuticals, developing potential new medicines for cardiac muscle dysfunction, and the raised funds will support its R&D pipeline, particularly innovative treatments for heart failure.
See More
Cytokinetics Raises $700M in Upsized Public Offering
- Upsized Offering: Cytokinetics successfully priced an upsized public offering of 9.86 million shares at $71 per share, raising approximately $700 million in gross proceeds before expenses, indicating strong market demand for its stock.
- Underwriter Option: The underwriters were granted a 30-day option to purchase up to an additional 1.48 million shares, further enhancing market confidence in Cytokinetics' future growth potential.
- Closing Timeline: The offering is expected to close on May 8, marking an active financing strategy for the company in the capital markets aimed at supporting its R&D and market expansion plans.
- Operating Expense Outlook: Earlier this week, Cytokinetics announced a proposed $650 million stock offering and outlined an operating expense range of $830 million to $870 million for 2026, reflecting the company's strategic planning for future growth.
See More
Cytokinetics Launches Corporate Giving Program for Non-Profits
- Program Launch: Cytokinetics has announced its annual Corporate Giving Program, which aims to provide charitable donations of up to $20,000 to eligible non-profit organizations to support equitable healthcare initiatives for cardiovascular disease and science education.
- Application Deadline: The deadline for applications for this program is August 3, 2026, encouraging 501(c)(3) organizations in the U.S. to apply, particularly those focused on science education and essential services for at-risk communities.
- Targeted Regions: The donations will primarily focus on the San Francisco Bay Area and Greater Philadelphia Region, aiming to enhance healthcare services and educational opportunities in these areas through funding health equity initiatives, thereby improving the quality of life for local residents.
- Corporate Mission: Diane Weiser, Senior Vice President of Cytokinetics, stated that this program reflects the company's commitment to the communities it serves, aiming to provide everyone with a fair chance at health and opportunity, further solidifying its image of social responsibility in the biopharmaceutical industry.
See More
Cytokinetics Launches MYQORZO in Germany Following U.S. Success
- European Market Launch: Cytokinetics has launched MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults, marking a significant expansion into the European market that is expected to enhance the company's market share in cardiovascular therapeutics.
- Clinical Trial Backing: The launch follows the European Commission's approval in February 2026, based on positive results from the SEQUOIA-HCM Phase 3 trial, which demonstrated robust efficacy and safety, improving patients' exercise capacity and symptoms, thereby reinforcing Cytokinetics' leadership in muscle biology.
- Significant Treatment Effects: Clinical data indicates that treatment with MYQORZO for 24 weeks resulted in a peak oxygen uptake (pVO2) increase of 1.76 mL/kg/min compared to baseline, versus 0.0 mL/kg/min in the placebo group, highlighting the drug's potential to significantly enhance patient quality of life.
- Increased Patient Hope: The availability of MYQORZO in Germany provides new treatment options for oHCM patients across Europe, reflecting Cytokinetics' commitment to the global HCM community and the potential to improve patient quality of life through personalized treatment approaches.
See More
Cytokinetics to Host Third Annual Muscle Biology Symposium
- Symposium Date and Venue: Cytokinetics will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium on May 29, 2026, at the Mission Bay Conference Center in San Francisco, CA, from 8 AM to 5 PM Pacific Time, aimed at fostering dialogue and discovery in muscle biology.
- Registration Details: The symposium is free for attendees, but capacity is limited, requiring interested parties to register online by May 22, 2026, reflecting the company's commitment to advancing scientific communication.
- Keynote and Agenda: The event will feature keynote presentations from distinguished experts covering cardiac biology, skeletal muscle biology, and emerging treatment modalities, with the goal of driving advancements in the biological understanding and treatment of muscle-related diseases.
- Company Background and Development: Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of pioneering innovations in muscle biology, currently developing multiple potential new medicines for cardiac muscle dysfunction, showcasing its ongoing investment and growth potential in the biopharmaceutical sector.
See More
Cytokinetics Presents Favorable Clinical Data for MYQORZO at ESC Heart Failure 2026
- Clinical Data Presentation: Cytokinetics showcased new clinical data for MYQORZO (aficamten) at the ESC Heart Failure 2026 Congress, emphasizing its effectiveness and safety compared to metoprolol, further solidifying its potential in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Sex Differences Analysis: The MAPLE-HCM trial revealed that MYQORZO demonstrated similar improvement effects in female patients compared to males, despite women entering the trial with more severe baseline characteristics, indicating the drug's consistent efficacy across genders, which may enhance personalized clinical treatment.
- Long-term Safety Data: A prospective analysis from FOREST-HCM indicated that long-term treatment with MYQORZO for up to 96 weeks did not increase the incidence of arrhythmias, reinforcing its safety profile, particularly in patients who discontinued beta-blocker therapy, thereby boosting confidence in its clinical application.
- Left Atrial Remodeling Improvement: Expanded insights from SEQUOIA-HCM provided the first analysis of MYQORZO's effects on left atrial function, showing significant improvements in left atrial mechanics, potentially offering new therapeutic avenues for enhancing functional capacity in oHCM patients.
See More
Cytokinetics Closes $805 Million Public Offering
- Offering Size: Cytokinetics successfully closed a public offering of 11,338,028 shares at $71.00 per share, raising approximately $805 million, indicating strong market demand for its stock.
- Underwriter Lineup: The offering was managed by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, reflecting confidence from investment banks in Cytokinetics' future growth and potentially enhancing its market position.
- Registration Statement: The securities were offered under a shelf registration statement filed with the SEC on February 27, 2025, ensuring compliance and streamlining the offering process, which boosts investor confidence.
- Business Context: Cytokinetics focuses on cardiovascular biopharmaceuticals, developing potential new medicines for cardiac muscle dysfunction, and the raised funds will support its R&D pipeline, particularly innovative treatments for heart failure.
See More
Cytokinetics Raises $700M in Upsized Public Offering
- Upsized Offering: Cytokinetics successfully priced an upsized public offering of 9.86 million shares at $71 per share, raising approximately $700 million in gross proceeds before expenses, indicating strong market demand for its stock.
- Underwriter Option: The underwriters were granted a 30-day option to purchase up to an additional 1.48 million shares, further enhancing market confidence in Cytokinetics' future growth potential.
- Closing Timeline: The offering is expected to close on May 8, marking an active financing strategy for the company in the capital markets aimed at supporting its R&D and market expansion plans.
- Operating Expense Outlook: Earlier this week, Cytokinetics announced a proposed $650 million stock offering and outlined an operating expense range of $830 million to $870 million for 2026, reflecting the company's strategic planning for future growth.
See More
